MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$41,092K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Stock-based compensation expense
Non-cash lease expense
Others
Negative Cash Flow Breakdown
Purchases of investments
Accounts payable
Lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-42,109
-49,122
-46,079
-50,582
Stock-based compensation expense
4,865
4,644
4,515
12,747
Non-cash lease expense
2,866
2,843
2,603
2,334
Depreciation expense
1,785
1,856
1,876
1,881
Amortization of premiums and discount on short-term investments
312
431
788
574
Change in fair value of short-term investment related party
0
0
539
1,454
Collaboration receivable related party
0
0
-
-120
Prepaid expenses and other current assets
-659
-1,221
-2,596
-1,297
Accounts payable
-6,518
3,552
-581
3,038
Accrued expenses and other current liabilities
880
-4,502
1,600
-1,070
Accrued settlement payment related party
-
-
0
0
Deferred revenue related party
-1,128
-856
-751
-1,175
Lease liabilities
-2,034
-1,915
-1,708
-1,601
Net cash used in operating activities
-41,046
-42,710
-37,256
-35,039
Maturities of investments
43,065
50,888
39,100
42,431
Sales of investments related party
-
-
5,400
-
Purchases of investments
18,989
7,283
15,880
134,306
Purchases of property and equipment
46
214
290
247
Return (payments) of security deposits
-
-
-
0
Return (payment) of security deposit
-
-
0
-
Net cash provided by (used in) investing activities
24,030
43,391
28,330
-92,122
Net proceeds from stock option exercises
23
393
408
373
Proceeds from espp offerings
338
-
144
0
Proceeds from issuance of common stock under the bms securities purchase agreement related party
-
-
0
0
Proceeds from follow-on offering, net of issuance costs
-
-
10
138,380
Proceeds from issuance of pre-funded warrants, net of issuance costs
-
-
0
0
Proceeds from research and development funding liability
0
0
0
6,000
Net cash provided by financing activities
361
393
562
144,753
Net change in cash, cash equivalents, and restricted cash
-16,655
1,074
-8,364
17,592
Cash, cash equivalents, and restricted cash at beginning of period
77,797
76,723
85,087
196,538
Cash, cash equivalents, and restricted cash at end of period
61,142
-
-
-
Cash, cash equivalents, and restricted cash at end of period
61,142
77,797
76,723
85,087
Less restricted cash
13,691
-
-
-
Total cash, and cash equivalents
47,451
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of investments
$43,065K
(202.21%↑ Y/Y)
Proceeds from espp
offerings
$338K
(71.57%↑ Y/Y)
Net proceeds from
stock option...
$23K
Net cash provided by
(used in) investing...
$24,030K
(153.43%↑ Y/Y)
Net cash provided by
financing activities
$361K
(-94.17%↓ Y/Y)
Canceled cashflow
$19,035K
Net change in cash,
cash equivalents,...
-$16,655K
(87.09%↑ Y/Y)
Canceled cashflow
$24,391K
Stock-based compensation
expense
$4,865K
(-59.48%↓ Y/Y)
Non-cash lease expense
$2,866K
(-39.80%↓ Y/Y)
Depreciation expense
$1,785K
(-49.92%↓ Y/Y)
Accrued expenses and
other current...
$880K
(152.07%↑ Y/Y)
Prepaid expenses and
other current assets
-$659K
(-1.07%↓ Y/Y)
Purchases of investments
$18,989K
(-65.62%↓ Y/Y)
Purchases of property and
equipment
$46K
(-98.85%↓ Y/Y)
Net cash used in
operating activities
-$41,046K
(54.53%↑ Y/Y)
Canceled cashflow
$11,055K
Net loss
-$42,109K
(59.70%↑ Y/Y)
Accounts payable
-$6,518K
(-346.13%↓ Y/Y)
Lease liabilities
-$2,034K
(0.93%↑ Y/Y)
Deferred revenue related
party
-$1,128K
(53.64%↑ Y/Y)
Amortization of premiums and
discount on short-term...
$312K
(-45.74%↓ Y/Y)
Buy us a coffee
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)